"Amarin upgraded to Buy from Neutral at Goldman Sachs Goldman Sachs analyst Paul Choi upgraded Amarin (AMRN) to Buy from Neutral with a $28 price target. The shares closed Thursday down $1.06 to $11.50. The 52% pullback in Amarin shares since December 13, 2019, which has been driven by both idiosyncratic and macro factors, makes the valuation "compelling" in the midst of the company's ongoing launch of Vascepa in the REDUCE-IT population, Choi tells investors in a research note. The analyst, who says ongoing patent litigation between Amarin and Dr. Reddy's (RDY) / Hikma has been an overhang on the stock, expects the ongoing launch of Vascepa to be successful over the near-term. He estimates approximately 8.7M patients are now eligible for Vascape in addition to the 3.5M previously eligible under the initial label. AMRN RDY
News 
Market Data 
Discover 
